Natco Pharma has reported a stark profit decline in the first quarter, largely driven by reduced sales of its leading cancer drug, lenalidomide. This led to a pronounced drop in consolidated revenues compared to the prior year. On a brighter note, the core business showed some positive growth, and total expenses saw a decrease, providing a silver lining to the financial report.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.